Nima Farzan - 11 Feb 2022 Form 4 Insider Report for Kinnate Biopharma Inc.

Role: Chief Executive Officer, Director
Signature: /s/ Mark A. Meltz, attorney in fact
Issuer symbol: N/A
Transactions as of: 11 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 15 Feb 2022, 15:00:45 UTC
Previous filing: 03 Jun 2021
Next filing: 03 Jun 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNTE	Employee Stock Option (right to buy)	Award	$0	+400,000		$0.000000	400,000	11 Feb 2022	Common Stock	400,000	$10.03	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	One forty-eighth (1/48th) of the total number of shares granted under the Option shall vest and become exercisable starting on March 1, 2022 (the "Vesting Commencement Date") and thereafter each month on the same day of the month as the Vesting Commencement Date, until all shares subject to the Option have vested on February 1, 2026, subject to the Reporting Person continuing to be a service provider through each such date.

Content

One forty-eighth (1/48th) of the total number of shares granted under the Option shall vest and become exercisable starting on March 1, 2022 (the "Vesting Commencement Date") and thereafter each month on the same day of the month as the Vesting Commencement Date, until all shares subject to the Option have vested on February 1, 2026, subject to the Reporting Person continuing to be a service provider through each such date.